{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:19:57Z","timestamp":1784762397744,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jchf.2024.05.007","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T14:45:52Z","timestamp":1719413152000},"page":"1750-1759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Vericiguat and Cardiovascular Outcomes\u00a0in Heart\u00a0Failure by Baseline\u00a0Diabetes Status"],"prefix":"10.1016","volume":"12","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Escobedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Refsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Roessig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert O.","family":"Blaustein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Anstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.05.007_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cardfail.2019.05.007","article-title":"Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart\u00a0Failure Society of America","volume":"25","author":"Dunlay","year":"2019","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2024.05.007_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S2213-8587(23)00128-6","article-title":"Predicting and preventing heart failure in type 2 diabetes","volume":"11","author":"Pandey","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jchf.2024.05.007_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2024.05.007_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.jchf.2024.05.007_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2024.05.007_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.05.007_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jchf.2024.05.007_bib8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.05.007_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril\u00a0in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.05.007_bib10","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.05.007_bib11","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejhf.1664","article-title":"Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart\u00a0Failure with Reduced Ejection Fraction) trial","volume":"21","author":"Pieske","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.05.007_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","article-title":"Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines\u2013Heart Failure registry","volume":"182","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2024.05.007_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10557-017-6754-x","article-title":"Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes","volume":"31","author":"Kristensen","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jchf.2024.05.007_bib14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0002-9149(97)89163-1","article-title":"Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry","volume":"77","author":"Shindler","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2024.05.007_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart\u00a0Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart\u00a0Failure Trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.05.007_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009337","article-title":"Vericiguat and Health-Related Quality of Life in Patients With Heart\u00a0Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial","volume":"15","author":"Butler","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.05.007_bib17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jchf.2022.12.014","article-title":"Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA","volume":"11","author":"Butler","year":"2023","journal-title":"JACC Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924004190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924004190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T21:07:03Z","timestamp":1759352823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924004190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2213177924004190"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.05.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vericiguat and Cardiovascular Outcomes\u00a0in Heart\u00a0Failure by Baseline\u00a0Diabetes Status","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}